Jacob Bell
Lead Reporter | @realjacobbellJacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. He can also be reached on Signal at realjacobbell.38.
1786 articles by Jacob Bell
-
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
Sept. 11, 2026 -
A booming business on Wall Street would love more biotechs to quietly die
Sept. 10, 2026 -
Novartis RNA drug falls short in rare muscle disease study
Sept. 8, 2026 -
This week in charts: Biotech’s rebound is undeniable
Aug. 28, 2026 -
Michael Polansky has a new, skin-focused biotech. Don’t call it a drug company.
Aug. 27, 2026 -
Amylyx’s bet on a GLP-1 blocker pays off
Aug. 18, 2026 -
EyePoint plummets on pivotal data for main drug
Aug. 17, 2026 -
Psychedelics developer Definium scores more positive data for LSD pill
Aug. 12, 2026 -
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
Aug. 10, 2026 -
Latigo IPO raises nearly $350M for pain drug development
Aug. 7, 2026 -
Takeda approval ushers in new wave of sleep drugs
Aug. 6, 2026 -
Vertex’s biggest overhang: a rival 50 times smaller
Aug. 4, 2026 -
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
Aug. 3, 2026 -
Alnylam plunges as earnings deliver ‘one-two punch’
July 30, 2026 -
MapLight CEO on what investors missed in the biotech’s schizophrenia data
July 29, 2026 -
MapLight dives despite positive data for schizophrenia drug
July 27, 2026 -
Vertex was sole bidder in high-premium Crinetics acquisition
July 22, 2026 -
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
July 22, 2026 -
Agios scraps sickle cell drug
July 21, 2026 -
Pain drugmaker Latigo outlines plans to go public
July 20, 2026 -
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
July 16, 2026 -
Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
July 14, 2026 -
GSK ends brain drug alliance with Alector
July 9, 2026 -
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
June 26, 2026 -
To Wall Street, psychedelics biotechs are more teammates than rivals
June 24, 2026
